Regis Healthcare Past Earnings Performance
Past criteria checks 0/6
Regis Healthcare's earnings have been declining at an average annual rate of -60.9%, while the Healthcare industry saw earnings declining at 3.3% annually. Revenues have been growing at an average rate of 7.4% per year.
Key information
-60.9%
Earnings growth rate
-60.9%
EPS growth rate
| Healthcare Industry Growth | 2.4% |
| Revenue growth rate | 7.4% |
| Return on equity | n/a |
| Net Margin | -2.1% |
| Next Earnings Update | 23 Feb 2025 |
Recent past performance updates
Recent updates
Investor Optimism Abounds Regis Healthcare Limited (ASX:REG) But Growth Is Lacking
Dec 20
Regis Healthcare Limited's (ASX:REG) P/S Is Still On The Mark Following 31% Share Price Bounce
Sep 12Is There An Opportunity With Regis Healthcare Limited's (ASX:REG) 38% Undervaluation?
May 02At AU$3.94, Is It Time To Put Regis Healthcare Limited (ASX:REG) On Your Watch List?
Mar 21Regis Healthcare (ASX:REG) Has Announced A Dividend Of A$0.0628
Feb 28Regis Healthcare Limited's (ASX:REG) CEO Compensation Looks Acceptable To Us And Here's Why
Oct 18Regis Healthcare (ASX:REG) Is Paying Out A Larger Dividend Than Last Year
Aug 29Regis Healthcare (ASX:REG) Is Paying Out Less In Dividends Than Last Year
Mar 01Is Regis Healthcare (ASX:REG) Using Debt Sensibly?
Oct 27Regis Healthcare's (ASX:REG) Shareholders Will Receive A Smaller Dividend Than Last Year
Aug 26Regis Healthcare Limited's (ASX:REG) Intrinsic Value Is Potentially 34% Above Its Share Price
Feb 25Is Regis Healthcare Limited (ASX:REG) Potentially Undervalued?
May 27Estimating The Fair Value Of Regis Healthcare Limited (ASX:REG)
May 09Should You Be Excited About Regis Healthcare Limited's (ASX:REG) 23% Return On Equity?
Aug 10At AU$1.32, Is Regis Healthcare Limited (ASX:REG) Worth Looking At Closely?
Aug 10Reflecting on Regis Healthcare's (ASX:REG) Share Price Returns Over The Last Five Years
Jul 14Is Regis Healthcare Limited (ASX:REG) An Attractive Dividend Stock?
Jul 02Revenue & Expenses Breakdown
How Regis Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,014 | -21 | 80 | 0 |
| 31 Mar 24 | 947 | -18 | 84 | 0 |
| 31 Dec 23 | 880 | -15 | 93 | 0 |
| 30 Sep 23 | 830 | -22 | 88 | 0 |
| 30 Jun 23 | 781 | -28 | 77 | 0 |
| 31 Mar 23 | 761 | -45 | 71 | 0 |
| 31 Dec 22 | 741 | -61 | 66 | 0 |
| 30 Sep 22 | 733 | -50 | 66 | 0 |
| 30 Jun 22 | 725 | -39 | 66 | 0 |
| 31 Mar 22 | 719 | -16 | 66 | 0 |
| 31 Dec 21 | 713 | 8 | 67 | 0 |
| 30 Sep 21 | 707 | 14 | 65 | 0 |
| 30 Jun 21 | 701 | 20 | 63 | 0 |
| 31 Mar 21 | 700 | 8 | 62 | 0 |
| 31 Dec 20 | 699 | -4 | 61 | 0 |
| 30 Sep 20 | 688 | -2 | 60 | 0 |
| 30 Jun 20 | 678 | -1 | 60 | 0 |
| 31 Mar 20 | 655 | 21 | 58 | 0 |
| 31 Dec 19 | 661 | 39 | 55 | 0 |
| 30 Sep 19 | 654 | 45 | 54 | 0 |
| 30 Jun 19 | 647 | 51 | 54 | 0 |
| 31 Mar 19 | 632 | 51 | 50 | 0 |
| 31 Dec 18 | 617 | 50 | 47 | 0 |
| 30 Sep 18 | 606 | 52 | 46 | 0 |
| 30 Jun 18 | 594 | 54 | 46 | 0 |
| 31 Mar 18 | 586 | 56 | 46 | 0 |
| 31 Dec 17 | 577 | 57 | 47 | 0 |
| 30 Sep 17 | 571 | 59 | 45 | 0 |
| 30 Jun 17 | 565 | 61 | 43 | 0 |
| 31 Mar 17 | 547 | 55 | 40 | 0 |
| 31 Dec 16 | 529 | 50 | 38 | 0 |
| 30 Sep 16 | 505 | 48 | 36 | 0 |
| 30 Jun 16 | 481 | 47 | 34 | 0 |
| 31 Mar 16 | 468 | 59 | 35 | 0 |
| 31 Dec 15 | 455 | 71 | 35 | 0 |
| 30 Sep 15 | 446 | 64 | 35 | 0 |
| 30 Jun 15 | 438 | 58 | 35 | 0 |
| 31 Mar 15 | 433 | 28 | 43 | 0 |
| 31 Dec 14 | 428 | -1 | 51 | 0 |
| 30 Sep 14 | 419 | 0 | 52 | 0 |
| 30 Jun 14 | 410 | 1 | 54 | 0 |
Quality Earnings: REG is currently unprofitable.
Growing Profit Margin: REG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: REG is unprofitable, and losses have increased over the past 5 years at a rate of 60.9% per year.
Accelerating Growth: Unable to compare REG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: REG is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-14.8%).
Return on Equity
High ROE: REG's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/10 08:44 |
| End of Day Share Price | 2025/02/10 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Regis Healthcare Limited is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Dunlop | BofA Global Research |
| David Stanton | CLSA |
| David Low | Deutsche Bank |